TY - JOUR
T1 - LifeTime and improving European healthcare through cell-based interceptive medicine
AU - Rajewsky, Nikolaus
AU - Almouzni, Geneviève
AU - Gorski, Stanislaw A
AU - Aerts, Stein
AU - Amit, Ido
AU - Bertero, Michela G
AU - Bock, Christoph
AU - Bredenoord, Annelien L
AU - Cavalli, Giacomo
AU - Chiocca, Susanna
AU - Clevers, Hans
AU - De Strooper, Bart
AU - Eggert, Angelika
AU - Ellenberg, Jan
AU - Fernández, Xosé M
AU - Figlerowicz, Marek
AU - Gasser, Susan M
AU - Hubner, Norbert
AU - Kjems, Jørgen
AU - Knoblich, Jürgen A
AU - Krabbe, Grietje
AU - Lichter, Peter
AU - Linnarsson, Sten
AU - Marine, Jean-Christophe
AU - Marioni, John C
AU - Marti-Renom, Marc A
AU - Netea, Mihai G
AU - Nickel, Dörthe
AU - Nollmann, Marcelo
AU - Novak, Halina R
AU - Parkinson, Helen
AU - Piccolo, Stefano
AU - Pinheiro, Inês
AU - Pombo, Ana
AU - Popp, Christian
AU - Reik, Wolf
AU - Roman-Roman, Sergio
AU - Rosenstiel, Philip
AU - Schultze, Joachim L
AU - Stegle, Oliver
AU - Tanay, Amos
AU - Testa, Giuseppe
AU - Thanos, Dimitris
AU - Theis, Fabian J
AU - Torres-Padilla, Maria-Elena
AU - Valencia, Alfonso
AU - Vallot, Céline
AU - van Oudenaarden, Alexander
AU - Vidal, Marie
AU - Voet, Thierry
PY - 2020/11
Y1 - 2020/11
N2 - Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.
AB - Here we describe the LifeTime Initiative, which aims to track, understand and target human cells during the onset and progression of complex diseases, and to analyse their response to therapy at single-cell resolution. This mission will be implemented through the development, integration and application of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during the progression from health to disease. The analysis of large molecular and clinical datasets will identify molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. The timely detection and interception of disease embedded in an ethical and patient-centred vision will be achieved through interactions across academia, hospitals, patient associations, health data management systems and industry. The application of this strategy to key medical challenges in cancer, neurological and neuropsychiatric disorders, and infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade.
U2 - 10.1038/s41586-020-2715-9
DO - 10.1038/s41586-020-2715-9
M3 - Book/Film/Article review
C2 - 32894860
SN - 0028-0836
VL - 587
SP - 377
EP - 386
JO - Nature
JF - Nature
IS - 7834
ER -